Seattle Genetics’ Antibody-Drug Conjugate Technology Utilized in Genentech’s Polivy, Now Approved by FDA

106

BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq:SGEN) today announced U.S. Food and Drug Administration (FDA) approval of Polivy™ (polatuzumab vedotin-piiq), which is an antibody-drug conjugate (ADC) targeting CD79b that utilizes Seattle Genetics’ technology. Polivy was developed and will be commercialized by Genentech, a member of the Roche Group. It was approved in combination with bendamustine plus Rituxan® (rituximab) (BR) for the treatment of adults with relapsed or refract…

 

http://www.businesswire.com/news/home/20190610005599/en/Seattle-Genetics%E2%80%99-Antibody-Drug-Conjugate-Technology-Utilized-Genentech%E2%80%99s